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Abstract
Background: Mutations in the fused in sarcoma (FUS) gene have been linked to amyotrophic lateral sclerosis (ALS).
ALS patients with FUS mutations exhibit neuronal cytoplasmic mislocalization of the mutant FUS protein.
ALS patients’ fibroblasts or induced pluripotent stem cell (iPSC)-derived neurons have been developed as models for
understanding ALS-associated FUS (ALS-FUS) pathology; however, pathological neuronal signatures are not sufficiently
present in the fibroblasts of patients, whereas the generation of iPSC-derived neurons from ALS patients requires
relatively intricate procedures.
Results: Here, we report the generation of disease-specific induced neurons (iNeurons) from the fibroblasts of patients
who carry three different FUS mutations that were recently identified by direct sequencing and multi-gene panel analysis.
The mutations are located at the C-terminal nuclear localization signal (NLS) region of the protein (p.G504Wfs*12, p.R495*,
p.Q519E): two de novo mutations in sporadic ALS and one in familial ALS case. Aberrant cytoplasmic mislocalization with
nuclear clearance was detected in all patient-derived iNeurons, and oxidative stress further induced the accumulation of
cytoplasmic FUS in cytoplasmic granules, thereby recapitulating neuronal pathological features identified in mutant FUS
(p.G504Wfs*12)-autopsied ALS patient. Importantly, such FUS pathological hallmarks of the patient with the p.Q519E
mutation were only detected in patient-derived iNeurons, which contrasts to predominant FUS (p.Q519E) in the nucleus
of both the transfected cells and patient-derived fibroblasts.
Conclusions: Thus, iNeurons may provide a more reliable model for investigating FUS mutations with disrupted NLS for
understanding FUS-associated proteinopathies in ALS.
Keywords: Amyotrophic lateral sclerosis, Fused in sarcoma, Human cell models, Induced neuron, Nuclear localization
signal, Stress granules, Neuronal cytoplasmic inclusion
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Background
Fused in sarcoma (FUS) is a multifunctional DNA/RNA-
binding protein involved in various aspects of cellular RNA
metabolism and executes its main functions predominantly
in the cell nucleus. Initially discovered as a fusion onco-
gene, mutations in the FUS gene resulting in FUS protei-
nopathies were recently linked to amyotrophic lateral
sclerosis (ALS), responsible for ~4 % of familial and ~1 %
of sporadic ALS cases [1–3]. FUS mutations cluster either
in the glycine-rich region of the protein or in the RGG-
rich C-terminal domain, where they disrupt the nuclear
localization signal (NLS) and result in altered subcellular
localization of the FUS protein. ALS-associated FUS (ALS-
FUS) mutations have been reported to cause cytoplasmic
mislocalization of the protein in the brain and spinal cord
of ALS patients [4, 5]. Moreover, cytoplasmic FUS tends to
aggregate to form inclusions in degenerating motor neu-
rons of ALS patients [6–8]. As a consequence, both toxic
gain-of-function in the cytoplasm and loss-of-function in
the nucleus are proposed to be causative events in ALS
development [9, 10].
Key pathological features have been documented based
on immunocytochemical studies on cultured fibroblasts
from ALS patients or immunohistological analysis on aut-
opsy samples [11, 12]. These studies revealed abnormal
cytoplasmic mislocalization of the FUS protein in ALS pa-
tients with FUS mutations in its NLS. When modeled on
fibroblasts, however, mutant FUS proteins were predomin-
antly detected in the nucleus, with minimal association
with pathological signatures detected with those mutations
in vivo [11, 13, 14]. Patient-derived induced pluripotent
stem cells (iPSC) with the ability to differentiate into neural
cells were found to be suitable for studying ALS-FUS path-
ology [15], but neuronal induction and differentiation pro-
cesses using iPSC require tedious and labor-intensive
procedures. Hence, it would be advantageous to develop
rapid and simple FUS-associated ALS patient-derived cell
models to study ALS-related neuronal pathology.
To overcome the limitations associated with the current
cell modeling systems, we examined FUS pathology in a
more disease-relevant cell model. We used our previously
described method of repressing a polypyrimidine-tract-
binding (PTB) protein to directly convert patient fibroblasts
carrying FUS mutations and those from age-matched
healthy controls into functional neurons (iNeuron) [16].
We have recently identified FUSmutations (p.G504Wfs*12,
p.R495*, and p.Q519E) by direct sequencing and multi-
gene panel testing [17–19]. In this study, we examined the
pathophysiological and biochemical properties of the three
different FUS mutations at NLS region. Analysis of brain
and spinal cord autopsy samples from FUS (p.G504Wfs*12)
patient demonstrated the expected pathologic features in-
cluding nuclear clearance and cytoplasmic accumulation of
FUS in neurons. To generate a cell model that recapitulates
key pathological features found in autopsy, we compared
cellular localization and aggregation-prone properties of
the endogenous FUS in fibroblasts, HEK-293 cells and rat
primary cortical neurons and directly converted iNeurons
in the presence or absence of stress. Directly converted
iNeurons from patient fibroblasts was the only model that
recapitulated the mutant FUS-associated neurological path-
ology that is observed in autopsied brain and spinal cord.
Moreover, we showed that the FUS neuropathology of the
familial ALS patient with p.Q519E mutation could be dem-
onstrated in directly converted iNeurons but not in trans-
fected cells or patient-derived fibroblasts. These findings
suggest that directly converted iNeurons have a potential to
become reliable disease-relevant models for dissecting
pathophysiologies of FUS-related proteinopathies in ALS.
Results and discussion
Clinical and genetic characteristics of three ALS patients
harboring FUS mutations in the NLS region
Among ten diverse, recently identified FUS mutants or var-
iants [17, 19], two de novo FUS mutants (p.G504Wfs*12,
p.R495*) confirmed by trio study in sporadic ALS [18] and
one FUS variant (p.Q519E) in familial ALS [19] were in-
cluded in this study. The residues of the three mutants are
located in the C-terminal region containing the nuclear
localization signal (NLS). As diagrammed in Fig. 1, the
Q519E mutation is a missense mutation in the C-terminal
NLS region; the mutation (p.G504Wfs*12) causes a frame
shift in exon 15, leading to a truncated FUS; and the muta-
tion (p.R495*) creates a premature codon to eliminate the
NLS. The mutation (p.R495*) is associated with an aggres-
sive clinical phenotype of ALS [20–22], and the mutation
(p.G504Wfs*12) is a pathogenic truncation mutant associ-
ated with sporadic ALS [18, 23]. In order to investigate
whether FUS (p.Q519E) variant has the significance in dis-
ease pathogenesis, we established structural analysis of the
mutation with Transportin-1 (Protein Data Bank, PDB (ID:
4FDD)) (Additional file 1: Figure S1). FUS is a nuclear pro-
tein that its nuclear import is mediated by interaction be-
tween Transportin-1 and the C-terminal NLS region of
FUS [24, 25]. Hence, we analyzed the hydrogen bonding
pattern of FUS-Transportin-1 complexes and observed
that one hydrogen bond is relevant to the FUS Q519 resi-
due. The distance between acceptor atom (oxygen; atom
type: OE1) of E509 from Transportin-1 and donor atom
(nitrogen; atom type: NE2) of Q519 from FUS was mea-
sured as 3.21 Å. Since the experimental structure has no
hydrogen atoms, the angle of hydrogen bond was mea-
sured between acceptor (OE1 of E509 from Transportin-
1), donor (NE2 of Q519 from FUS), and the prior atom
connected on donor (CD of Q519 from FUS), which comes
to 134.7°. This is a possible hydrogen bonding between
FUS-Transportin-1 complexes. If the Q519 on FUS is mu-
tated to E519, the length of side chain is decreased by one
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carbon chain (from 4 to 3) and the polar property changes
to negative from neutral. In the end, the found Q519
(FUS)-E509 (Transportin-1) hydrogen bond in wild-type
will disappear in the Q519E mutant. In addition, the
negative-negative repulsion (E519-E509) in Q519E mutant
may result in the deactivation on FUS-Transportin-1 bind-
ing, thus providing a significance of the FUS (p.Q519E)
variant in disease pathogenesis.
Detailed clinical and epidemiological characteristics of
three ALS patients with different FUS mutations, one
sporadic ALS patient, and four healthy controls enrolled
in this study are summarized in Table 1.
FUS pathology in ALS-FUS patient brain and spinal motor
neurons
Human autopsy samples were used to reveal the distri-
bution of FUS in the brain and spinal cord of FUS
(G504Wfs*12) patient compared to a normal control
(CTL 4) and a sporadic ALS patient without any known
mutation. Immunohistochemical profiles demonstrated
that wild-type FUS was confined predominantly to the
nucleus in the majority of neurons in the control brain.
A similar distribution of FUS immunoreactivity was
also seen in a sporadic ALS patient. In contrast, prom-
inent cytoplasmic or decreased nuclear staining of FUS
with ring-like perinuclear inclusions was observed in
the FUS (G504Wfs*12) case (Fig. 2a). To confirm cyto-
plasmic accumulation of FUS in neuronal cells from
the FUS (G504Wfs*12) patient, we performed double-
label immunohistochemistry for NeuN (neuronal nuclei
marker) and FUS. This demonstrated co-labeling of
NeuN in the nucleus and the mutant FUS in the cyto-
plasmic of the same neurons from the ALS-FUS pa-
tient, in contrast to the localization of the FUS protein
in the nucleus of neurons from healthy control and a
sporadic ALS patient (Fig. 2b, Additional file 2: Figure S2).
We also determined the pathogenic features of the mu-
tant FUS in spinal cord motor neurons. Consistent with
findings in the precentral motor cortex, immunohisto-
chemistry for FUS in NeuN-positive cells revealed the
same pathological feature in the ventral horn of spinal
cords (Fig. 2c, d). The sections of spinal cords from both
Table 1 Patients and controls whose skin fibroblasts were studied
Characteristic ID MND Sex Exon FUS
genotype
Age at
biopsy, yr
Age of
onset, yr
Familial
history
Site of
onset
ALSFRS-
R
delta-
FS
Survival,
mo
Autopsy
ALS-FUS HS374 777 M 15 Q519Ea 34 34 Yes Limb 46 0.10 >61 c N/A
HS131 402 F 14 G504Wfs*12b 34 31 No Limb 36 0.92 46 Yes
HS197 502 F 14 R495*b 31 27 No Bulbar 23 1.92 54 N/A
Sporadic ALS HS250 551 M N/A N/A N/A 57 No N/A 39 0.82 68 Yes
CTL 1 N/A N/A F N/A N/A 35 N/A N/A N/A N/A N/A N/A N/A
CTL 2 N/A N/A F N/A N/A 40 N/A N/A N/A N/A N/A N/A N/A
CTL 3 N/A N/A M N/A N/A 45 N/A N/A N/A N/A N/A N/A N/A
CTL 4 N/A N/A N/
A
N/A N/A N/A N/A N/A N/A N/A N/A N/A Purchased
FUS, fused in sarcoma, ALSFRS-R a revised ALS functional rating scale, ALS amyotrophic lateral sclerosis, F female, N/A not applicable, M male, CTL control
ALSFRS-R and delta FS were evaluated at the first visit
aReported previously (Kim H-J et al., 2015). bReported previously (Kwon MJ et al., 2012; Kim YE et al., 2014).
c>61 means that more than 61 months have passed since symptom onset and the patient is still alive on the last follow-up
Fig. 1 Schematic diagram of functional domains of the FUS protein with gene mutations identified in patients with ALS are provided. All three
patients enrolled in this study have FUS mutations (p.G504Wfs*12, p.R495*, p.Q519E) that affect the NLS region. Q/G/S/Y rich = Gln/Gly/Ser/Tyr-rich
domain; RGG = Arg/Gly/Gly-rich motifs; E = nuclear export signal; RRM = RNA-recognition motif; ZnF = zinc-finger motif; L = nuclear
localization signal
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the normal controls and the sporadic ALS patient demon-
strated FUS in the nucleus of those neurons. By contrast,
mutant FUS were excluded from the nucleus of ALS-FUS
patient neurons.
Interestingly, FUS was predominantly nuclear in the
postcentral gyrus and dorsal horn neurons of FUS
(p.G504Wfs*12) patient indicating that FUS abnormal-
ities are FUS abnormalities are observed in the motor
Fig. 2 Cytoplasmic incorporation of FUS is present in ALS-FUS patient brain and spinal cords. a DAB staining depicts cytoplasmic neuronal inclusions
of FUS (as indicated by their morphology) in the precentral gyrus of FUS (p.G504Wfs*12) patient (bottom) compared to the nucleus staining of FUS in
a normal control (CTL 4, top) and a sporadic ALS patient (middle). Prominent cytoplasmic or decreased nucleus staining of FUS with ring-like
perinuclear inclusions were observed in the motor neurons of the ALS patient. The enlarged images are shown in the right panels. Scale bars = 10 μm.
b FUS pathology was confirmed by double-label immunofluorescence for FUS (green) and NeuN (red) in a normal control (top), sporadic ALS patient
(middle), and FUS (p.G504Wfs*12) patient (bottom). Boxed region in the left panel is enlarged in the right panels. Note that cytoplasmic FUS expressed
in a normal control are microglia (Additional file 2: Figure S2). Cells were counter stained with the nuclear marker DAPI (blue). Scale bars = 50 μm for
the merged left panels and 7.5 μm for the right panels. c The ventral horn of the cervical spinal cord sections from normal control (top), sporadic ALS
patient (top), and FUS (p.G504Wfs*12) patient (bottom) were compared. The same pathological features were observed by DAB staining in the spinal
cords of the FUS (p.G504Wfs*12) patient. Scale bars = 10 μm. d The corresponding sections were processed for double-label immunofluorescence.
FUS pathology was confirmed by FUS (green) and NeuN (red) staining. Cells were counter stained with the nuclear marker DAPI (blue). Scale bars = 10 μm
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system to a greater extent than that observed for the pa-
tient sensory neurons (Additional file 3: Figure S3). This
is the first report on the case of FUS (p.G504Wfs*12)
pathology on autopsy ALS samples.
Endogenous mutant FUS pathology in primary patient
fibroblasts
The residues of the three mutants (p.G504Wfs*12, p.R495*,
p.Q519E) are all located in the C-terminal NLS-containing
domain of FUS. To examine the presence of ALS-FUS
pathology in ALS patient fibroblasts, a punch skin biopsy
were obtained from normal controls and ALS patients to
isolate their fibroblasts. Primary fibroblasts from healthy
individuals (CTL 1, 2, and 3) showed endogenous FUS en-
tirely in the nucleus (Fig. 3a, left panels). Contrary to the re-
port showing endogenous neuronal FUS harboring the
G504Wfs*12 or R495* mutation in the cytoplasm with de-
creased staining in the nucleus [26], we observed more
abundant nuclear immunoreactivity of FUS and somewhat
diffuse cytoplasmic immunoreactivity on patient-derived
fibroblasts that harbor either the G504Wfs*12 or R495*
mutation. Surprisingly, FUS (p.Q519E) did not even show
any cytosolic mislocalization. These results suggested that
either FUS (p.Q519E) does not contribute to the pathogenic
potential of ALS or that its mislocalization failed to be cap-
tured in the fibroblast model.
Stress agents are known to induce cytoplasmic granules,
and various ALS-causing FUS mutations have previously
been reported to be recruited to those stress granules
under stress conditions [21]. Sodium arsenite (referred to
as arsenite) is widely used to induce oxidative stress in
cells. To determine whether the cytoplasmic FUS protein
in the patient fibroblasts could be recruited into stress
granules, we stressed cells with arsenite, and observed the
shift of dispersed FUS G504Wfs*12 or R495* proteins to
cytoplasmic stress granules, which is similar to the re-
sponse of the eukaryotic translation initiation factor 4G
(eIF4G) (Fig. 3a, right panels, and Fig. 3b, c). Again, the
Q519E mutant remained in the nucleus under such stress
conditions. In addition to oxidative stress induced by so-
dium arsenite, we tested hyperosmotic stress induced by
0.4 M sorbitol for 1 hr [7]. In response to sorbitol stress,
the amount of FUS in the cytoplasm increased with
corresponding decrease in the nucleus. Importantly, the
accumulation of cytoplasmic FUS granules in mutant
fibroblasts is clearly much greater than that in healthy
controls (Additional file 4: Figure S4).
Subcellular fractionation of fibroblasts was performed
to further investigate the localization of endogenous
FUS. In agreement with the immunofluorescence results,
the shorter G504Wfs*12 and R495* mutants could be
distinguished from the longer wild-type FUS by Western
blotting, showing that the mutants were more detectable
in the cytosol and that the wild type was exclusively
detected in the nucleus. In contrast, the Q519E mutant
was detected in only the nucleus (Fig. 3d). These data
suggest that patient-derived fibroblasts may not fully re-
flect the ALS pathology with disease-associated muta-
tions in FUS.
Mutant FUS pathology in transfected HEK-293 cells and
primary neurons
We aimed to examine whether the similar mutant FUS
characteristics of patient fibroblasts, carrying the Q519E
mutation, i.e., predominant nucleus FUS staining, was
also observed in transfected cells. We overexpressed the
cDNA encoding an N-terminal green fluorescence pro-
tein (GFP)-tagged wild-type or a mutant FUS in HEK-
293 cells. The transiently transfected G504Wfs*12 and
R495* mutants showed both nuclear and cytosolic distri-
bution, whereas the Q519E mutant like the wild-type
FUS resided predominantly in the nucleus (Fig. 3e, left
panels). To determine whether the cytoplasmic mutant
FUS could be incorporated into stress granules under
oxidative stress conditions, we exposed the cells to arse-
nite. Both the G504Wfs*12 and R495* mutants showed
the incorporation of their cytoplasmic FUS into eIF4G-
containing granules, but the Q519E mutant still behaved
like the wild-type FUS (Fig. 3e, right panels).
The neuropathology of ALS is characterized by degen-
erating neurons in the brain and spinal cord, which is
coincident with neuronal cytoplasmic inclusions of ALS-
associated FUS proteins [27]. To determine the distribu-
tion of wild-type or mutant FUS constructs in neurons,
we cultured cortical neurons from rats on embryonic day
18 rats and transfected them with GFP-tagged FUS con-
structs. The neurons were first cultured for 21 days and
then transfected for 48 hrs before fixation. As shown in
HEK-293 cells, both G504Wfs*12 and R495* mutants re-
sided largely in the cytosol, which is contrary to the pat-
terns that were observed in patient fibroblasts (Fig. 3f, left
panels). When rat cortical neurons were exposed to oxida-
tive stress, the cytosolic FUS (p.G504Wfs*12 and p.R495*)
was further incorporated in eIF4G-positive stress granules
(Fig. 3f, right panels). Interestingly, both the Q519E mu-
tant and the wild-type FUS continued to reside in the nu-
cleus before and after stress induction. These findings
suggest that neurons from murine models may fail to re-
flect certain neuronal pathologies in human ALS-FUS
brain or spinal cord samples. Moreover, overexpressed
FUS may also cause deleterious effects that may be unre-
lated to ALS pathologies in transfected cells [28].
Endogenous mutant FUS that recapitulates autopsied ALS
pathology is iNeuron-specific
To develop more accurate disease models for ALS, we
trans-differentiated ALS patient fibroblasts into induced
neurons (iNeurons) by repressing a single RNA binding
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polypyrimidine-tract-binding (PTB) protein. To generate
human iNeurons, we infected both patient and control
fibroblasts with a lentivirus-repressing PTBP1, according
to and modified from our recently published methods
[16]. The subsequent culture conditions are provided in
the schematic overview in Fig. 4a. In confocal cellular im-
munostaining assays, cells exhibited typical neuronal
morphology, and nearly all cells were strongly positive for
TUJ1 (the early neuronal marker βIII-tubulin). Within a
day of neuronal induction, the cells were positive for
TUJ1, and from 5–21 days, an increase in MAP2 (neur-
onal dendrites marker) immunostaining was observed
(Fig. 4b). The maturated morphology of iNeurons with
dendritic branching were confirmed with MAP2, NeuN
(neuronal nuclei marker), and synapsin (neuronal synapsis
marker) immunostaining at day 10 of neuronal induction
(Fig. 4c). The percentage of neuronal tubulin marker
TUJ1-positive iNeuron cells of the controls and three ALS
patients with different types of FUS mutations were simi-
lar (Fig. 4d).
(See figure on previous page.)
Fig. 3 Endogenous FUS is partially mislocalized in patient fibroblasts with G504Wfs*12 and R495* mutations. a Primary fibroblasts cultures
examined by confocal microscopy. A representative control image shows intense staining for FUS (green) in the nuclei (DAPI) and the stress
granule markers eIF4G (red) in the cytoplasm. Patients with the G504Wfs*12 and R495* mutations near the NLS region also show that a majority
of FUS protein in the nuclei with a slight increase of cytoplasmic FUS. In response to oxidative stress conditions, cytoplasmic FUS-positive inclusion
bodies of G504Wfs*12 and R495* mutation co-localized with eIF4G stress granules (red). Cells were counter stained with the nuclear marker DAPI
(blue). Scale bars = 25 μm. Bar graphs represent b the numbers of stress granules and c the numbers of FUS-positive stress granules (SGs). Data are
from three experiments (the mean ± SEM, n = 20). One-way ANOVA followed by Tukey multiple comparisons test; **p < 0.001; N.S., not significant.
d Cell fractionation analysis of cultured fibroblasts from ALS patients and controls showing an increased cytoplasmic expression of FUS in G504Wfs*12
and R495* patients compared with a representative control and Q519E patient. The upper band of FUS in the nucleus fraction of FUS (p.R495*) patient
fibroblasts presumably an allele without a mutation and the lower band indicates the allele with the truncated R495* fragment. Lamin B2 and GAPDH
are loading controls for the nuclear and cytoplasmic fractions, respectively. e HEK-293 cells were transfected with green fluorescent protein
(GFP) wild-type FUS or FUS containing the ALS-associated mutations and treated with vehicle or 0.5 mM arsenite for 30 min. The cells were
then processed for immunofluorescence analysis. Localization of GFP-tagged FUS wild type or the indicated FUS mutations (green), eIF4G
stress granules (red) are shown. Cytosolic eIF4G co-localizes with FUS aggregates after oxidative stress. GFP (green) and eIF4G (red) show an
increased overlap between mutant FUS (p.G504Wfs*12, p.R495*) and eIF4G as compared to wild-type FUS (WT) and eIF4G. Nuclei are shown
by DAPI staining. Scale bars = 10 μm. f Rat E18 primary cortical neurons were cultured for 21 days and were transfected with constructs expressing
wild-type FUS or ALS-associated mutants of FUS (green). After stress, redistribution of mutant FUS aggregates (green) into eIF4G (red) under oxidative
stress is demonstrated. Nuclei are shown by DAPI staining. Scale bars = 25 μm.
Fig. 4 Direct conversion. a Schematic of the experimental protocol. b Cells probed with a mature neuronal marker anti-MAP2 (green) and a tubu-
lin marker anti-TUJ1 (red) revealed that mature iNeurons are detected from day 7. Cells were counter stained with the nuclear marker DAPI (blue).
Scale bars = 250 μm. c Expression of mature neuronal markers in iNeurons. Green: MAP2, NeuN, Synapsin; red: TUJ1; blue: DAPI. Scale bars: 50 μm.
d Quantification of iNeurons based on TUJ1-positive cells divided by the number of initial plating cells in response to PTBP1 shRNA. Cells un-
treated with shPTBP1 had no TUJ1-positive staining. Data are from three experiments (the mean ± SEM, n = 30–82).
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In control iNeurons, endogenous FUS was predomin-
antly nuclear (Fig. 5a and b left panels). In contrast, the
patient iNeurons of G504Wfs*12 or R495* exhibited re-
duced endogenous FUS immunoreactivities in the nu-
cleus along with increased cytoplasmic FUS. Considering
that FUS was predominantly distributed in the nucleus
of patient fibroblasts, FUS expression in iNeuron models
seem to more closely mirror the FUS neuropathology
found in ALS patients than those observed in patient
fibroblasts. Intriguingly, the FUS (p.Q519E) patient also
showed cytoplasmic localization of FUS with less nuclear
distribution in the iNeuron model.
To determine whether the cytosolic FUS (p.Q519E)
could be induced to stress granules in iNeurons, we
treated iNeurons with arsenite, and in line with the results
with the cytoplasmic FUS in G504Wfs*12 or R495* pa-
tient iNeurons, we observed co-localization of the FUS
(p.Q519E) mutant with arsenite-induced stress granules,
which was further validated by the detection of the colo-
calization of the Ras-GTPase-activating protein SH3 do-
main binding protein (G3BP), another known component
of stress granules (Fig. 5b, right panels). Co-localization of
the cytosolic FUS inclusions with eIF4G under oxidative
stress was also confirmed and quantified (Additional
file 5: Figure S5, and Fig. 5c, d). These findings suggest
that unlike patient-derived fibroblasts and transfected
cell models, only patient iNeurons are able to fully cap-
ture the neuropathology of FUS mutations with a dis-
rupted NLS region.
Conclusions
Mutations in FUS have been strongly implicated as the
genetic cause of ALS [2, 29]. In this study, we performed
functional analysis of three different FUS mutations found
in ALS patients, including the two de novo mutations
(p.G504Wfs*12, p.R495*) we previously identified by trio
study in sporadic ALS [30] and a novel variant (p.Q519E)
by multi-gene panel testing in familial ALS (Table 1). All
these mutations were located in the C-terminal region that
contains the nuclear localization signal (NLS). FUS accu-
mulation in neuronal cytoplasmic inclusions along
with a degree of nuclear clearance are histopatho-
logical hallmarks of patients with FUS-mediated ALS,
especially for the mutations located at the NLS region
[2, 31]. Consistently, we show for the first time that
FUS (p.G504Wfs*12) exhibited the accumulation of
cytoplasmic FUS and the depletion of nuclear FUS in
patient brain and spinal cord motor neurons. The aut-
opsy results demonstrated typical ALS-FUS features of
cytoplasmic aggregation and nuclear clearance of FUS
in neurons, which have also been described in the aut-
opsy of patients with other FUS mutations in the NLS
region.
As of now, cultured patient fibroblasts have been used
as cellular models for disease studies. Induced pluripotent
stem cell (iPSC)-derived neurons from patients with a
FUS mutation appear to provide a suitable model for un-
derstanding pathophysiological mechanisms of FUS muta-
tions; however, one of the problems in skin fibroblast
models is that some common FUS-associated pathological
hallmarks found in autopsy cases are not consistently
identified in patient fibroblasts [13]. Although iPSC-based
models are useful in identifying the molecular and cellular
defects in neuronal abnormality and instrumental for in
vitro drug screening for therapeutic effects, the process of
generating iPSC-derived neurons from human fibroblasts
is intricate. To develop disease models more efficiently,
we directly converted the fibroblasts from patients with
FUS mutations into induced neuron (iNeuron) by repres-
sing a polypyrimidine-tract-binding (PTB) protein. As
PTB is naturally down-regulated during neuronal induc-
tion in development, PTB regulation enhanced the neuro-
genesis program in the fibroblasts [16]. As shown in the
present data, iNeuron is a rapid and highly disease-
relevant cell model. Compared to the majority of nuclear
FUS distribution in patient fibroblasts carrying mutations
in the NLS region, iNeurons demonstrated a clear increase
in cytoplasmic distribution and a concurrent decrease in
the nuclear distribution of mutant FUS. Moreover, cyto-
solic aggregates of FUS could be induced under oxidative
stress conditions. The analysis on iNeurons from a FUS
(p.G504Wfs*12) patient recapitulated all key features of
FUS pathology found in the patient brain and spinal
cord motor neurons, thus confirming that iNeurons as
a more disease-relevant in vitro model that accurately
mirrors disease pathology of the patient. Intriguingly,
the FUS (p.Q519E) patient who had endogenous FUS
distributed in only the nucleus in fibroblast models or
transiently transfected cells demonstrated a cytosolic
mislocalization and aggregation of FUS only in the
iNeuron model. These findings further support this
new model as a useful research tool for studying ALS-
FUS pathogenesis.
FUS proteinopathies in ALS neuronal degeneration
have been poorly understood due to the lack of clinically
relevant cell models for the disease. The identification of
disease-causing genes and the development of patient-
specific and disease-relevant cell models for functional
analysis are critical for advancing our understanding of
the pathophysiology in ALS. Studies using patient iNeur-
ons may reveal additional features of FUS pathology in
the cytoplasm that may have escaped previous studies
on patient fibroblasts [11]. Similarly, mutant FUS cDNA
constructs of patients whose fibroblasts or each cDNA
construct does not display typical FUS pathology may
have distinct pathologic features, which can now be dis-
sected in iNeurons.
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Fig. 5 (See legend on next page.)
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ALS-FUS patient fibroblast models present endogen-
ous cytoplasmic FUS incorporation into stress granules;
however, FUS in patient fibroblasts are predominantly
expressed in the nucleus. Murine neurons transiently
transfected with mutant FUS constructs revealed both
decreases in the nucleus and increases in the cytosol,
and upon stress, cytosolic FUS could be induced into
stress granules. Yet, murine neurons may be insufficient
to capture all key mechanism in neuronal pathology in
human brain or spinal cords.
Development of more disease-relevant experimental
models from ALS patients that recapitulate the characteris-
tics of neuronal dysfunction found in human post-mortem
tissues will open new doors to both understanding patho-
physiologic mechanisms in ALS-FUS and developing new
therapeutic strategies. Therefore, simple, reliable, and re-
producible iNeuron models are promising in that they may
greatly accelerate ALS research.
Methods
Subjects
Three ALS patients with different types of FUS mutations
were enrolled in this study. We have recently identified
FUS mutations (p.G504Wfs*12, p.R495*, and p.Q519E) by
direct sequencing and multi-gene panel testing [17, 19, 32].
These patients showed onset at age 27 to 34 with various
disease progression. Skin fibroblasts were obtained from
these ALS patients with disrupted NLS region and three
healthy controls. Autopsy tissues were obtained from two
patients: one ALS-FUS patient (p.G504Wfs*12) and one
sporadic ALS patient without any known mutation in
FUS, C9orf72, SOD1, ALS2, SPG11, UBQLN2, DAO, GRN,
SQSTM1, SETX, MAPT, TARDBP, and TAF15. The clin-
ical and genetic findings are summarized in Table 1. The
study protocol was approved by the Institutional Review
Board of Hanyang University Hospital, and written in-
formed consents were obtained from all patients involved
in the study (IRB# 2011-R-63).
Structural modelling
For a structural analysis, we sought for an applicable
protein structure in PDB (ID: 4FDD), which contains
Transportin-1 and FUS domains. Because the FUS
domain includes the Q519 residue, the influence of
Q519E mutation on the complex can be examined. The
PDB complex consists of Transportin-1 (chain A: resi-
due number from 371 to 890) and FUS (chain B: residue
number from 498 to 526). The missing part (residue
number from 321 to 370) and N-terminal region (from 1
to 320) in Transportin-1 was removed from the original
PDB structure because they are not relevant to direct in-
teractions with the FUS domain. The FUS missing resi-
dues from 498 to 506 were generated and minimized to
find their local minima with keeping the rest atomic co-
ordinates unchanged. To examine the effect of Q519E
mutation on the FUS-Transportin-1 binding, a hydrogen
bonding analysis was performed between FUS and
Transportin-1 structures. Because the structure has no
hydrogen atoms, we used an implicit hydrogen bonding
analysis with the following loose criteria, the bond dis-
tance below 5 Å between acceptor and donor atom and
the angle above 90°, among acceptor, donor, and the
prior atom connected to the donor atom. The analysis
was performed in CHARMM (Chemistry at Harvard
Macromolecular Mechanics) [33], and the structure was
visualized using Jmol (an open-source Java viewer for
chemical structures in 3D. http://www.jmol.org/)
Immunohistochemistry and immunofluorescence
Autopsied samples of brain and spinal cord were ob-
tained from one ALS-FUS patient (p.G504Wfs*12), one
sporadic ALS patient, and one healthy control. Immuno-
histochemistry was performed on 5 μm thick paraffin
sections. Tissues were deparaffinized, rehydrated in ser-
ial changes of xylene and ethanol gradients and auto-
claved for 10 min in 10 mM citric acid, pH 8.0. Sections
were then blocked with 10 % normal goat serum (vol/
vol) in PBS. For immunostaining, rabbit polyclonal anti-
bodies reactive to FUS (Abnova) were applied on the pre-
central motor cortex and postcentral gyrus, and mouse
antibodies against FUS (Proteintech) were used on spinal
cord tissue. The sections were colorimetrically developed
using the 3,3’-diaminobenzidine DAB substrate kit (Vector
Labs) for 1 min and counter stained with haematoxylin
(Sigma-Aldrich), dehydrated, and coverslipped in Permount
(See figure on previous page.)
Fig. 5 Endogenous FUS is mislocalized to the cytoplasm and is incorporated into cytoplasmic stress granules in response to arsenite in patient
iNeurons. a A representative control shows intense staining for FUS (green) in the nuclei (DAPI) in TUJ1-positive (red) iNeurons at day 10 of neuronal
induction, whereas the patients show a majority of FUS protein in the cytoplasm. Cells were counter stained with the nuclear marker DAPI (blue). Scale
bars = 50 μm. b Confocal images of vehicle treated iNeurons (left panel) as compared to cells treated with 0.5 mM arsenite for 30 min (right panel) at
day 10 are shown. A representative control shows FUS protein predominantly localized to the nuclei. ALS-FUS patient with Q519E mutation recapitulated
the FUS neuropathology only in iNeurons: iNeurons from the patient show a majority of FUS protein (green) in the cytoplasm. In response to oxidative
stress conditions, cytoplasmic FUS-positive inclusion bodies (green) in iNeurons were co-localized with G3BP stress granules (red). Cells were fixed and
probed by immunofluorescence for DAPI (blue). Scale bars = 25 μm. Bar graphs represent (c) the numbers of stress granules and (d) the numbers of FUS-
positive stress granules (SGs). Data are from three experiments (the mean ± SEM, n= 20). One-way ANOVA followed by Tukey multiple comparisons test;
**p< 0.001; N.S., not significant
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medium. Images were acquired with a Leica DM5000B
microscope.
For double labeling immunofluorescence, paraffin-
embedded sections were blocked with 10 % normal goat
serum (vol/vol). The primary antibodies used were mouse
antibodies against FUS (Proteintech) and rabbit polyclonal
antibodies against NeuN (Millipore), GFAP (Dako), and
Iba-1 (Wako). The secondary antibodies included Alexa
Fluor 488-conjugated mouse and tetramethylrhodamine
B isothiocyanate (TRITC)-conjugated rabbit antibodies.
Images were acquired using a Leica TCS SP5 confocal
microscope.
Plasmids and site-directed mutagenesis
N-terminally GFP-tagged wild-type human FUS cDNA was
cloned into the pReceiver vector (Genecopoeia). To make
the mutant DNA (p.Q519E, p.G504Wfs*12, p.R495*),
in vitro mutagenesis of the GFP-tagged FUS cDNA
was conducted using the EZchange™ site-directed mu-
tagenesis kit (Enzynomics) according to the manufac-
turer’s protocol.
Cell culture and reagents
HEK-293 cells were cultured in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 10 % fetal bo-
vine serum (Gibco), sodium bicarbonate, sodium pyruvate
(Sigma-Aldrich), and antibiotics. Primary rat neurons were
maintained in Neurobasal medium supplemented with
2 % (vol/vol) B27, 1 % (vol/vol) GlutaMAX, 100X insulin-
transferrin-selenium (ITS) (all from Invitrogen), and
antibiotics.
HEK-293 and primary rat neurons were transiently
transfected with GFP-tagged wild-type or mutant human
FUS cDNA using Lipofectamine 2000 (Invitrogen) ac-
cording to the manufacturer’s instructions. After 48 hrs,
the cells were fixed in the presence or absence of stress
for immunofluorescence staining as described below.
For oxidative stress induction, vehicle (water) or 1 M
stock solution of sodium arsenite (Sigma-Aldrich) dis-
solved in water was added to the media at a final concen-
tration of 0.5 mM for up to 30 min. For hyperosmotic
stress induction, vehicle (growth media) or 0.4 M sorbitol
(Sigma-Aldrich) dissolved directly into the growth media
for up to 1 hr.
Conversion of human skin fibroblasts to iNeurons
Fibroblasts were obtained from forearm skin with a
punch biopsy (Table 1). Fibroblasts were cultured and
maintained in DMEM supplemented with 20 % FBS,
non-essential amino acids (all from Gibco), sodium bi-
carbonate (Sigma-Aldrich), and 1 % (vol/vol) Penicillin/
Streptomycin/Fungizone (Cellgro). In all experiments,
passage-matched fibroblasts (passages 3–5) were used.
Fibroblast were seeded at a density of 1 × 104 cells/cm2
and used for experiments after cell synchronization by
serum starvation at matched time points.
For direct conversion, human fibroblasts were seeded
onto matrigel (BD Biosciences)-coated 24-well tissue cul-
ture dishes or cell culture flasks (Nunc). Induced neurons
(iNeurons) were generated from patient-derived fibro-
blasts using lentiviral transduction of the shRNAs against
human PTBP1 (Sigma-Aldrich MISSION) according to
our previously described protocol [16, 34]. Thirty hours
after the shRNA treatment, the cells were selected with
1 μg/ml puromycin for another 30 hrs. Selected cells
were replaced for 3 days in N3 media (DMEM/F12
(Gibco) supplemented with 25 μg/ml Insulin, 50 μg/ml
apo-transferrin, 20 nM progesterone, 100 nM putres-
cine, and 30 nM sodium selenite (all Sigma-Aldrich)),
10 ng/ml bFGF (Gibco), supplemented with BDNF,
CNTF, GDNF, and NT3 (all PeproTech) as previously
described [16]. From day 4 to the day of analysis, the
cells were maintained in N3 media supplemented with
2 % FBS.
Immunocytochemistry and confocal microscopy
Fibroblasts, HEK-293, primary rat neurons, and iNeur-
ons were washed with 1 × PBS, fixed with 4 % parafor-
maldehyde (PFA) for 15 min at room temperature and
then washed three more times with PBS. Cells were
permeabilized by incubation in 0.3 % Triton X-100 for
10 min at room temperature, washed with PBS, and then
blocked for 1 hr in 5 % normal goat serum (Vector
Labs). Cells were incubated with primary antibodies for
2 hrs at room temperature, washed three times with 1 ×
PBS, and incubated with secondary antibodies for 1 hr at
room temperature. After three additional washings with
1 × PBS, nuclei were stained with DAPI. Coverslips were
mounted on glass slides with Fluoromount-G (Southern-
Biotech). The primary antibodies used included mouse
monoclonal antibodies against C-terminus FUS (Santa
Cruz Biotechnology), FUS (Proteintech), G3BP (BD
Transduction Laboratories), and rabbit polyclonal anti-
bodies against eIF4G (Santa Cruz Biotechnology), FUS
(Abnova). For neuronal cell markers, mouse monoclonal
antibody reactive to β-tubulin III (TUJ1; Covance) and
rabbit polyclonal antibody to MAP2 (Cell Signaling
Technology), NeuN (Millipore), and Synapsin I (Chemi-
con) were used. Secondary antibodies were Alexa Fluor
488-conjugated and/or TRITC-conjugated mouse or
rabbit antibodies (Gibco). Images were acquired with a
Leica TCS SP5 confocal microscope. The stress granules
were counted manually. Twenty cells from each patient fi-
broblasts or iNeurons were chosen based on DAPI staining
of nuclei (n = 3). Significance between stress granule for-
mations was calculated using one-way ANOVA followed
by Tukey multiple comparisons test.
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Nuclear-cytoplasmic fractionation and immunoblot analysis
Cell fractionation was performed using the NE-PER
Nuclear and Cytoplasmic Extraction Reagents kit (Thermo
Fisher Scientific) according to the manufacturer’s protocol.
Nuclear and cytoplasmic extracts from fibroblasts were
analyzed by Western blotting. Equal amounts of protein
from each sample were separated by 10 % sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to a PVDF membrane (GE Healthcare).
Membranes were blocked with 5 % skim milk. The pri-
mary antibodies used were mouse monoclonal antibodies
against Lamin B2 (AbCam) and rabbit polyclonal anti-
bodies against FUS (Abnova) and GAPDH (Santa Cruz
Biotechnology). The membranes were probed with horse-
radish peroxidase-conjugated secondary antibodies (Santa
Cruz Biotechnology) and developed using West-Q Chemi-
luminescent Substrate Plus Kits (GenDEPOT).
Additional files
Additional file 1: Figure S1. Structures of FUS-Transportin-1 complexes.
(a) Overall structure of FUS-Transportin-1 complexes are presented in blue
sphere and white surface, respectively. The position of FUS (p.Q519) is
marked by red sphere models. (b) The focused view around the mutation
(p.Q519). The structure of FUS and Transportin-1 complexes are consisted
of a ball-and-stick representation. Stick models are colored by atom (N:
blue, O: red, C: gray, respectively). The important position of the mutation
(p.Q519) is depicted in a red ball-and-stick representation. A possible
hydrogen bonding between Q519 of FUS and E509 of Transportin-1 is
shown in the red circle with the acceptor-donor distance (3.21 Å).
(PDF 69 kb)
Additional file 2: Figure S2. FUS is distributed in the cytoplasm in
microglia but is absent in astrocytes. FUS (green) is (a) apparently not
expressed in GFAP-positive astrocytes, (red) and is (b) cytoplasmic in
Iba-1-positive microglia (red, arrows) in the precentral gyrus of a normal
control (CTL 4, top), sporadic ALS patient (middle), and FUS (p.G504Wfs*12)
patient (bottom). Boxed region in the left panel is enlarged in the right
panels. Cells were counter stained with the nuclear marker DAPI (blue).
Scale bars = (a) 50 μm for the merged left panels and 10 μm for the right
panels, and (b) 25 μm. Cells were counter stained with the nuclear marker
DAPI (blue). (PDF 594 kb)
Additional file 3: Figure S3. FUS is distributed in the nucleus in ALS-
FUS patient postcentral gyrus and dorsal horn. (a) DAB staining depicts
predominant nucleus localization of FUS (as indicated by their morphology)
in the postcentral gyrus of a normal control (CTL 4, top), sporadic ALS patient
(middle), and FUS (p.G504Wfs*12) patient (bottom). The enlarged images are
shown in the right panels. Scale bars = 10 μm. (b) The dorsal horn of the
spinal cord sections from normal control (top), sporadic ALS patient (top),
and FUS (p.G504Wfs*12) patient (bottom) were compared. The same
predominant nucleus staining of FUS were observed by DAB staining
in the dorsal horn neurons (as indicated by their morphology) of a normal
control (top), sporadic ALS patient (middle), and FUS (p.G504Wfs*12) patient
(bottom). Scale bars = 10 μm. (PDF 378 kb)
Additional file 4: Figure S4. Endogenous FUS is partially redistributed
to the cytoplasm in response to sorbitol. Primary fibroblasts of a
representative control and the patient with the Q519E mutation shows
intense staining for FUS (green) in the nuclei (DAPI) and the stress granule
markers eIF4G (red) in the cytoplasm. Patients with the G504Wfs*12 and
R495* mutations also show that a majority of FUS protein in the nuclei with
a slight increase of cytoplasmic FUS (left panel). Cells treated with 0.4 M
sorbitol for 1 hr are shown on the right panel. In response to sorbitol stress,
slight decrease of nucleus FUS and increase of cytoplasmic FUS-positive
inclusion bodies co-localized with eIF4G stress granules were observed.
The accumulation of cytoplasmic FUS granules in mutant fibroblasts were
much greater than that in healthy controls. Cells were counter stained with
the nuclear marker DAPI (blue). Scale bars = 10 μm. (PDF 821 kb)
Additional file 5: Figure S5. Endogenous FUS cytoplasmic
incorporation into stress granule marker eIF4G in response to arsenite in
patient iNeurons. Immunocytochemistry performed on vehicle treated
iNeurons (left panel) as compared to cells treated with 0.5 mM arsenite for
30 min (right panel) at day 10 are shown. A representative control shows FUS
protein predominantly localized to the nuclei. All three ALS-FUS patients
show a majority of FUS protein (green) in the cytoplasm of iNeurons. Cyto-
plasmic FUS-positive inclusion bodies (green) were detectable in eIF4G-
positive stress granules (red) in patients. Cells were fixed and probed by im-
munofluorescence for DAPI (blue). Scale bars = 25 μm. (PDF 751 kb)
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